Diabetes Market Research UAE

The UAE diabetes pharmaceutical market is one of the most commercially significant therapy area markets in the GCC, driven by a national adult diabetes prevalence of approximately 19% (IDF Diabetes Atlas 2023) — among the highest globally, ranking the UAE fourth in the world by age-adjusted adult diabetes prevalence. The total diabetes pharmaceutical market spans insulin (basal, bolus, and premixed analogue insulins), oral antidiabetic agents (metformin, DPP-4 inhibitors, SGLT2 inhibitors), GLP-1 receptor agonists (including the rapidly growing semaglutide segment), and newer combination products. Key commercial players include Novo Nordisk (dominant in insulin and GLP-1 agonists with Ozempic, Victoza, Rybelsus, and the insulin portfolio), Sanofi (Lantus, Toujeo, and Soliqua), Eli Lilly (Trulicity, and the insulin Humalog/Basaglar portfolio), AstraZeneca (Bydureon, Farxiga/dapagliflozin — a major SGLT2 inhibitor player), and Merck/MSD (Januvia/sitagliptin — a leading DPP-4 inhibitor). The biosimilar insulin segment is growing, with Indian manufacturers (Biocon/Mylan) and European biosimilar entrants competing on price in the MOH and DHA formulary segments. GLP-1 receptor agonists are experiencing the fastest growth, driven by the dual indication of diabetes management and weight loss — the UAE's high obesity rates amplify this commercial opportunity beyond the diabetes indication alone.

UAE diabetes drug access operates through three distinct formulary channels, each with different coverage criteria and therapeutic substitution policies. The DHA Essential Drug List covers insured Dubai residents: metformin, sulfonylureas, and older insulin formulations are broadly listed; branded GLP-1 agonists and newer branded SGLT2 inhibitors are on the DHA formulary but may require prior authorisation or are restricted to specialist prescribers (endocrinologists or diabetologists) rather than general practitioners. The DOH/Daman Abu Dhabi formulary is similar in structure but historically more conservative on biosimilar insulin substitution: Daman has approved biosimilar insulins for listing but maintains prescriber authority over biologic-biosimilar switching in insulin. The MOHAP National Formulary covers public hospital facilities in the northern emirates and has a more cost-focused formulary committee that tends to prefer generic and biosimilar alternatives over branded originator products wherever bioequivalence is established. For novel, high-cost diabetes agents — such as the fixed-ratio GLP-1/basal insulin combinations or the GLP-1/GIP agonist tirzepatide (Mounjaro, Eli Lilly) — UAE formulary access requires a full payer dossier including clinical evidence of superiority over listed alternatives, budget impact modelling, and payer advisory board validation of the target population definition.

Treatment pathway research in the UAE diabetes market consistently reveals a complex two-tier prescribing system. General practitioners and family medicine physicians in polyclinic settings manage the majority of newly diagnosed and stable type 2 diabetes patients — particularly in the primary care polyclinic networks that have expanded significantly under both DHA and DOH primary care development programmes. GPs typically initiate treatment with metformin and make first-line oral antidiabetic agent choices. However, treatment intensification decisions — switching to injectable therapy, initiating GLP-1 agonists or SGLT2 inhibitors for cardioprotective or renal-protective indications, or managing poorly controlled patients — are predominantly made by endocrinologists and diabetologists at the specialist level. The GP-to-specialist referral trigger is typically documented HbA1c above 8–9% despite 3–6 months of oral therapy, or the presence of cardiovascular or renal comorbidities that activate the guideline-recommended use of SGLT2 inhibitors or GLP-1 agonists. BioNixus treatment pathway research maps this referral trigger landscape through physician surveys (n=50–100 GPs, n=40–60 endocrinologists) and patient journey IDIs, identifying the specific decision points where commercial intervention has the highest impact.

Ramadan fasting is a clinically and commercially significant context for diabetes management in the UAE and across GCC markets. An estimated 50–80% of Muslim patients with type 2 diabetes choose to fast during Ramadan despite medical advice, creating a well-documented period of increased clinical risk — hypoglycaemia risk with sulfonylureas and insulin, dehydration risk with SGLT2 inhibitors, and adherence disruption across multiple drug classes. For pharmaceutical market research, Ramadan has three important implications. First, patient journey research must include the Ramadan dimension explicitly: how patients adjust their medication regimens, how physicians advise patients about fasting management, and where the current standard of care is inadequate creates important positioning opportunity for drugs with Ramadan-specific management data (such as basal insulins with low hypoglycaemia risk profiles). Second, HCP research should include Ramadan-specific prescribing decision scenarios: which drugs GPs and endocrinologists prefer for patients who insist on fasting, and what clinical support they use for Ramadan fasting guidance. Third, research timing matters: conducting patient adherence research during Ramadan will capture non-representative behaviour; scheduling studies immediately after Eid to capture the behavioural reflection period is typically more productive for understanding normal treatment adherence patterns.

Patient recruitment for UAE diabetes qualitative research is feasible but requires careful design for several UAE-specific reasons. The UAE diabetes patient population is approximately 88% expatriate, reflecting the national demographic structure: a large portion of patients are South Asian (Indian, Pakistani, Bangladeshi), Arab (Egyptian, Levantine, Arab expatriate), and East Asian, with a smaller proportion of UAE nationals. This demographic diversity means that Arabic and Urdu/Hindi language IDI and FGD instruments are required alongside English for representative patient recruitment — English-only research will systematically under-represent South Asian patients, who are disproportionately prevalent in the UAE diabetes patient population due to genetic predisposition. UAE national patients (approximately 12% of the diabetes patient population) are typically recruited through DHA or DOH clinical network referral rather than open panel recruitment, as UAE nationals are more likely to be engaged with public healthcare networks and SEHA facilities. Patient recruitment through clinic partnerships — diabetes clinics within SEHA hospitals, DHA polyclinic networks, and major private hospital endocrinology departments — is the most effective channel, typically achieving 70–80% recruitment success from clinic referral compared to 20–30% from panel or social media outreach. A target of 20–30 patient IDIs across 4–6 weeks is achievable through clinic network recruitment for most common diabetes sub-populations.

The UAE is at an early but definite stage of movement toward outcomes-based pricing (OBP) for high-cost diabetes products, particularly within the Abu Dhabi DOH and Daman framework. Daman has begun exploring managed-entry agreements for selected high-cost products, and DOH health economics advisors have expressed interest in outcomes-linkage mechanisms for products where real-world outcomes in UAE patients may differ from trial outcomes in predominantly non-UAE populations. For GLP-1 agonists and SGLT2 inhibitors — where the clinical evidence for cardiovascular and renal outcomes is strong in international trial populations but UAE real-world data are limited — a credible OBP framework would require UAE-specific RWE commitments. BioNixus has conducted payer advisory boards in Abu Dhabi in which Daman medical directors explicitly identified outcomes-based access as a preferred model for novel high-cost diabetes agents. For pharmaceutical teams considering UAE access strategy for premium diabetes products, BioNixus recommends including an OBP feasibility assessment as part of payer primary research — specifically probing whether DOH/Daman decision-makers would be open to an outcomes-linkage arrangement and what outcomes metrics they would specify.